FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4386232078> ?p ?o ?g. }

• W4386232078 endingPage "481" @default.
• W4386232078 startingPage "480" @default.
• W4386232078 abstract "India carries the highest share of the global tuberculosis (TB) burden. In 2021, there was a 19% increase in TB patients from 2020. The WHO ‘End TB’ strategy sets a goal to reduce TB deaths by 90% between 2015 and 2035.[1] Although the initiative has been started to achieve this goal, it resulted in a small decline in the disease burden. Hence, efforts need to be increased exponentially. To meet this target, it requires not only improving active TB case diagnosis and their effective treatment but also strategic plans to prevent the development of new infection.[2] Many of the modelling studies from China and India suggested that it is not possible to achieve the 2035 target or even the 2050 elimination goal without combining active TB treatment with the diagnosis and treatment of an individual with latent tuberculosis infection (LTBI).[3] Latent TB is basically defined as a state of persistent immune response to simulation by Mycobacterium tuberculosis antigen without evidence of clinically manifested active TB. It can lead to active TB disease in approximately 5–10% of these individuals during their lifetime. This reactivation risk depends upon various factors like age when they are infected, the presence of many other associated medical conditions like diabetes, HIV, etc.[4] Diagnosis of LTBI is important, and early initiation of prophylaxis treatment for positive patients can prevent the development of active TB. The diagnostics method is a century-old tuberculin skin test (TST) but still being widely used. Newly emerged interferon-gamma release assay (IGRA) can diagnose LTBI more accurately in people vaccinated with Bacillus Calmette-Guerin (BCG). Novel emerging skin tests have been developed in recent years: Diaskintest (Generium Pharmaceutical, Moscow, Russia), C-Tb skin test (Statens Serum Institut, Copenhagen, Denmark), and EC-Test (Zhifei Longcom Biologic Pharmacy Co., Anhui, China).The Diaskintest is a new effective way to identify the initial presentation of TB and developed based on a fusion protein of the early secreted antigenic target 6 (ESAT-6) and culture filtrate protein 10 (CFP-10) antigens present in virulent strains of M. tuberculosis, which are absent in the BCG strain and in most NTMs. The novel C-Tb skin test is based on a mixture of antigens ESAT-6 and CFP10. The EC-Test is the latest skin test for the diagnosis of TB and LTBI. All these tests have higher specificity than that of the TST and are more accurate, acceptable, and cheaper alternatives to IGRAs.[5] Isoniazid (INH) for LTBI treatment has a longer duration of therapy and poor tolerability, while shorter, better-tolerated treatment using rifamycin provides a safe and effective alternative to INH. Hence, CDC recommended once weekly regimen of isoniazid plus rifapentine for three months (3 HP) and a daily rifapentine regimen of one month.[6,7] Even though latent infections are treated in countries having low TB burden such as the United States, various views state that this approach is not possible and cannot be implemented in high-burden countries like India. The main reason lies in the fact that, in India, re-infection due to contact with active disease cases rather than reactivation contributes to a high disease burden.[4] Hence, achieving the WHO pre-defined LTBI target for TB elimination may sound like a ‘colossal task’. In such a situation risk group, prioritisation for LTBI testing and treatment, radiological screening and shorter treatment for LTBI is really worth. For higher TB incidence countries like us, implementing an effective LTBI treatment programme represents both challenge and opportunity. Though many challenges are there in the journey to achieve this target, more research on LTBI in terms of novel biomarkers which can differentiate persons with LTBI at risk for the development of active TB and active steps in their management, cost-effective shorter regimens can definitely direct our path towards the goal. Financial support and sponsorship Nil. Conflicts of interest There are no conflicts of interest." @default.
• W4386232078 created "2023-08-29" @default.
• W4386232078 creator A5017861072 @default.
• W4386232078 creator A5026724840 @default.
• W4386232078 creator A5046861654 @default.
• W4386232078 creator A5083755098 @default.
• W4386232078 date "2023-01-01" @default.
• W4386232078 modified "2023-10-08" @default.
• W4386232078 title "Diagnosis and treatment of latent tuberculosis infections in high burden settings: A Herculean task" @default.
• W4386232078 cites W2529780328 @default.
• W4386232078 cites W2807977107 @default.
• W4386232078 cites W2958129076 @default.
• W4386232078 cites W3006864167 @default.
• W4386232078 cites W3210271900 @default.
• W4386232078 doi "https://doi.org/10.4103/lungindia.lungindia_163_23" @default.
• W4386232078 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37787369" @default.
• W4386232078 hasPublicationYear "2023" @default.
• W4386232078 type Work @default.
• W4386232078 citedByCount "0" @default.
• W4386232078 crossrefType "journal-article" @default.
• W4386232078 hasAuthorship W4386232078A5017861072 @default.
• W4386232078 hasAuthorship W4386232078A5026724840 @default.
• W4386232078 hasAuthorship W4386232078A5046861654 @default.
• W4386232078 hasAuthorship W4386232078A5083755098 @default.
• W4386232078 hasBestOaLocation W43862320781 @default.
• W4386232078 hasConcept C126322002 @default.
• W4386232078 hasConcept C142724271 @default.
• W4386232078 hasConcept C177713679 @default.
• W4386232078 hasConcept C203014093 @default.
• W4386232078 hasConcept C2776247216 @default.
• W4386232078 hasConcept C2777975735 @default.
• W4386232078 hasConcept C2779134260 @default.
• W4386232078 hasConcept C2779806340 @default.
• W4386232078 hasConcept C2780639635 @default.
• W4386232078 hasConcept C2781069245 @default.
• W4386232078 hasConcept C3019041143 @default.
• W4386232078 hasConcept C71924100 @default.
• W4386232078 hasConceptScore W4386232078C126322002 @default.
• W4386232078 hasConceptScore W4386232078C142724271 @default.
• W4386232078 hasConceptScore W4386232078C177713679 @default.
• W4386232078 hasConceptScore W4386232078C203014093 @default.
• W4386232078 hasConceptScore W4386232078C2776247216 @default.
• W4386232078 hasConceptScore W4386232078C2777975735 @default.
• W4386232078 hasConceptScore W4386232078C2779134260 @default.
• W4386232078 hasConceptScore W4386232078C2779806340 @default.
• W4386232078 hasConceptScore W4386232078C2780639635 @default.
• W4386232078 hasConceptScore W4386232078C2781069245 @default.
• W4386232078 hasConceptScore W4386232078C3019041143 @default.
• W4386232078 hasConceptScore W4386232078C71924100 @default.
• W4386232078 hasIssue "5" @default.
• W4386232078 hasLocation W43862320781 @default.
• W4386232078 hasLocation W43862320782 @default.
• W4386232078 hasOpenAccess W4386232078 @default.
• W4386232078 hasPrimaryLocation W43862320781 @default.
• W4386232078 hasRelatedWork W1989604051 @default.
• W4386232078 hasRelatedWork W2042792659 @default.
• W4386232078 hasRelatedWork W2051035669 @default.
• W4386232078 hasRelatedWork W2051786017 @default.
• W4386232078 hasRelatedWork W2153916113 @default.
• W4386232078 hasRelatedWork W2155142592 @default.
• W4386232078 hasRelatedWork W2291224386 @default.
• W4386232078 hasRelatedWork W2947492592 @default.
• W4386232078 hasRelatedWork W2964312908 @default.
• W4386232078 hasRelatedWork W17846074 @default.
• W4386232078 hasVolume "40" @default.
• W4386232078 isParatext "false" @default.
• W4386232078 isRetracted "false" @default.
• W4386232078 workType "article" @default.